Despite being in existence for >40 years, the application of telemedicine has lagged significantly in comparison to its generated interest. Detractors include the immobile design of most historic telemedicine interventions and the relative lack of smartphones among the general populace. Recently, the exponential increase in smartphone ownership and familiarity have provided the potential for the development of mobile health (mHealth) interventions that can be mirrored realistically in clinical applications. Existing studies have demonstrated some potential clinical benefits of mHealth in the various phases of solid organ transplantation (SOT). Furthermore, studies in nontransplant chronic diseases may be used to guide future studies in SOT. Nevertheless, substantially more must be accomplished before mHealth becomes mainstream. Further evidence of clinical benefits and a critical need for cost-effectiveness analysis must prove its utility to patients, clinicians, hospitals, insurers, and the federal government. The SOT population is an ideal one in which to demonstrate the benefits of mHealth. In this review, the current evidence and status of mHealth in SOT is discussed, and a general path forward is presented that will allow buy-in from the health care community, insurers, and the federal government to move mHealth from research to standard care.
Introduction
Telemedicine has been in existence for almost as long as organ transplantation. Nevertheless, despite its generated interest, prospective study and application have lagged significantly. This is especially true in outcome studies involving a provider-patient interaction with solid organ transplantation (SOT) patients; a Cochrane review in 2015 reported only one randomized controlled trial, out of 93, that was in the transplant population (1) .
There have been multiple reasons for this lack of applicability. Historically, a major issue was the immobility of most telemedicine therapies, which required patients and clinicians to be in strictly defined locations at specific times. With the advent of the smartphone and mobile medical devices, the widespread expansion of the subcategory of mobile health (mHealth) became possible. Despite this, smartphones had low penetrance in the populations that could benefit from mHealth the most, namely, the underserved. The most recent Gallup poll, however, demonstrated that the presence of smartphones has rapidly expanded from 35% of the population in 2011 to 64% in 2015, with 20% of smartphone users reporting that their smartphones are their primary or only means of accessing the Internet (2) . In addition, the predominant drivers of the increase in smartphone ownership have been young adults, adults with low household incomes and low levels of educational attainment, and nonwhite persons (2) . This rapidly increasing trajectory may have been assisted by the increasing availability of affordable smartphones and plans and the availability of free wireless networking in the community. With this exponential growth in the integration of smartphones, the potential for real-time mHealth monitoring is now achievable for a substantial proportion of the population, including the SOT community.
The purpose of this paper is to review and discuss studies in the SOT population throughout the phases of transplant, to illustrate changes in the prevalence and acceptance of mHealth devices, to describe lessons learned from studies in other conditions, and to outline challenges and opportunities for future widespread implementation.
Pretransplant Phase
Waitlist Studies of the use of mHealth in candidates for SOT have focused on improving quality of life and knowledge (Table 1) (3) (4) (5) . Of note, recent studies assessing the impact of mHealth on quality of life in this population have limited results and are restricted to measuring feasibility and identifying themes for future interventional studies (3, 4) . These are important early steps in the production of research and can be used by interested researchers to identify gaps and needs. Examples of other topics that may be of interest to the those managing the waitlist are use of mHealth reminders to coordinate patients through the evaluation phase and placement on the waitlist more quickly and reminders to keep labs, serum, and insurance information up to date.
Procurement
A major challenge in the current era of organ procurement is assessing the likelihood of marginal or complex donor organs to be transplanted and used in a successful manner. A number of recent case series and feasibility studies have been published both internationally and in the United States (Table 1) (6) (7) (8) (9) . These studies highlight several potential modalities for visualizing organs or tissue through digital means or utilizing telemedicine to gain second opinions on marginal grafts.
These technologies have the potential to help with realtime allograft selection and to serve as a reservoir to keep data on organ use for internal quality reviews. In addition, they provide the possibility of organizing a specialty service to share expertise in the assessment and transplant of marginal organs via review from multiple centers. Such a service could provide consultation to professionals at centers that have minimal experience working with marginal donors.
Living donor advocacy
With the plateau of deceased donor availability over the past decade, there has been continued interest in increasing living donation (10, 11) . Sieveredes et al used questionnaires to identify themes and evaluate attitudes, acceptance, and preferences for remote education in the living donor process to improve access and to reduce travel costs (4) . These authors demonstrated high acceptability and prevalence of mobile platforms for viewing the educational material but also determined that potential donors and recipients had differing educational needs that necessitated individualized educational material. Using a guided Facebook application (app), Kumar et al were able to demonstrate a significant increase in live donor referrals compared with a control group (odds ratio [OR] 6.61, 95% CI 2.43-17.98; p < 0.001) (12) . Interestingly, there were no significant differences in activity or "shares" between patients who received a donor referral compared with those who did not, indicating that the tool may be valuable even for those with a previously limited or nonexistent social media presence.
These studies highlight the significant number of possibilities for individual and mass education about living donation and the potential for increasing living donor referral through altruistic donors. One of the most difficult conversations waitlisted patients have is the face-to-face request for potential donors to step forward. Educational programs via mHealth can help patients navigate these situations and increase the footprint of their request to the mass population.
Posttransplant Phase
Education, willingness, acceptability, and satisfaction Technology has been found to be an effective means to educate people on a number of topics. In the posttransplant phase, two groups have demonstrated significant improvements in knowledge of the risk of skin cancer by using video education either alone or in combination with individualized reminders (Table 2) (13, 14) . Converting paper education to video format may significantly increase knowledge about various subjects. It is unknown exactly why this information format has a greater effect on patients; possible explanations could include an increased ability to hold a patient's interest and to bypass deficits in reading and comprehension levels. Further evaluation of video education, possibly coupled with individualized reminders, has tremendous potential to improve the downstream effects of limited knowledge and low health literacy. Unfortunately, simply improving knowledge may not be enough to show significant improvements regarding complex issues such as adherence. Suhling et al were unable to demonstrate clinically significant improvements in the proportion of calcineurin inhibitor (CNI) levels within the desired range when comparing tablet-based and standard education in a population of lung transplant recipients with less than half of their CNI levels in range at baseline (15) .
One of the most important changes to the field of mHealth has been access and willingness to use portable devices for health care needs. In two surveys of kidney ESRD, end-stage renal disease; IRD, increased risk donor; mHealth, mobile health; PHS, Public Health Service; RCT, randomized controlled trial; tMBSR, telephone-adapted mindfulness-based stress reduction; tSupport, telephone-adapted structural support group. (Continued ) (Continued ) (Continued ) (Table 2 ) (16, 17) . Furthermore, 78% were willing to incorporate mHealth into their care, provided it did not increase costs (17) . This mirrors the 77% of liver transplant recipients at another center that felt mHealth monitoring would be helpful for postoperative care (18) .
In addition, patients who have participated in mHealth or telemedicine trials have demonstrated high satisfaction among respondents (Table 2 ) (19, 20) . The combination of high willingness and satisfaction rates provides a good prognosis for further studies. These results, however, may be limited by the low response rates in some studies and the apparent discordance in reported willingness and sustained utilization over time (Table 2 ) (19, 21, 22) .
Although many interventional clinical trials have demonstrated reasonable attrition rates, many others have a significant decrease in use over time. The study by Jiang et al on the Pocket PATH app in lung transplant recipients had very high acceptance, intent to use, and ratings of perceived usefulness and ease of use at baseline but failed to show concordance with actual utilization. Only 48% of patients had high daily use in the first 2 mo, and that amount decreased further to 19% in months 6-12 (23) . In another trial, only 33% of lung transplant recipients performed self-monitoring with the Pocket PATH app on ≥50% of the days on which they were expected to self-monitor in the studied year, and 40% of participants performed the self-monitoring on <25% of the expected days (21) .
Adherence
Posttransplant adherence remains one of the most important factors for long-term allograft survival, and mHealth interventions may be able to affect at-risk populations. Although some adherence tools are too complex and costly for use outside clinical trials (24), many have real-world applicability (Table 2) . With simple text message reminders, for example, McKenzie et al were able to significantly increase adherence to laboratory monitoring in 33 adolescent liver transplant recipients over a 1-year period (78% vs. 58%, p < 0001), whereas a concurrent control group demonstrated no change in adherence (57% vs. 61%, p = 0.38) (25) . However, outside of lab work reminders, simple text messaging has largely failed to show significant improvements in selfmanagement of long-term illnesses in the general population (26) . Multimodal mHealth interventions have had the most success for long-term effectiveness. In a 20-patient cohort with <85% adherence to medications, McGillicuddy et al compared patients receiving an mHealth intervention, including a wireless electronic medication tray with timestamping and alert capabilities, a Bluetooth-enabled blood pressure (BP) monitor, and a smartphone, to patients receiving usual care. The mHealth system attempted to improve adherence through a series of device-, patient-, and coordinatorlevel alerts in the event that a medication had not been taken at the appropriate time. Patients were reminded at regular intervals to measure their BP daily and were contacted if they were nonadherent. If the results of the BP measurements were outside of safe ranges, the coordinator was alerted. A provider-tailored weekly report was delivered to the physician. Throughout the 3-mo intervention, there was a 91% retention rate, and both adherence and BP were significantly improved in the mHealth group (27) . Another well-designed mHealth intervention, the Pocket PATH app, was able to demonstrate improved self-monitoring (OR 5.11, 95% CI 2.95-8.87; p < 0.001) and adherence (OR 1.64, 95% CI 1.01-2.66; p = 0.046) in a large prospective randomized trial (21) . Another study was able to demonstrate a 90% response rate to critical messages with the Pocket PATH, although there was no control group (22) . Demonstrating the effect of multiple layers of mHealth interventions, Reese et al demonstrated significantly improved adherence with both customized reminders (78%) and customized reminders with notification to providers for adherence <90% (88%) compared with usual care (55%, p < 0.001 for each intervention group compared with controls) (28).
It is important for future studies to be large enough to achieve statistical power in comparisons between intervention groups, so as to identify the level of intervention that maximizes improved outcomes without becoming overly intrusive or burdensome on patients and providers.
Control of chronic conditions
Despite the prevalence of chronic conditions in SOT recipients, mHealth studies are sorely lacking (Table 2) . In a follow-up to their 3-mo BP and adherence study, McGillicuddy et al demonstrated that patients who had received mHealth continued to demonstrate improved BP control 12 mo after the end of the intervention compared with the control group (131 vs. 155 mmHg, p = 0.004) (29) . In another study, Aberger et al used home-based BP monitoring with pharmacist-managed care to significantly improve blood pressure in kidney transplant recipients within 30 days (30) . Unfortunately, studies focusing on allograft outcomes have not been as successful. Neither a prospective study comparing computer-and nurse-based triage for clinical intervention nor the long-term follow-up of the previously described randomized trial on the Pocket PATH app were able to demonstrate significant differences in lung transplant outcomes compared with controls, perhaps indicating that more easily modulated surrogate end points may be more successful than hard end points of allograft outcomes (Table 2 ) (31,32).
Outside of the transplant population, a intervention similar to that of McGillicuddy et al demonstrated improved BP control in black and Hispanic patients with uncontrolled hypertension, demonstrating the external validity (33) . Several larger studies, comparing home BP monitoring mHealth interventions and pharmacist titration with usual care, demonstrated significant BP improvements versus physician management with or without pharmacist consultations (34, 35) . Magid et al performed a randomized controlled trial in 10 clinics where 348 uncontrolled hypertensive patients were randomized either to home BP measurement and pharmacist-led titration or to usual care. Despite similar baseline BP, the intervention group had significantly better BP control (128.1 vs. 137.4 mmHg for systolic BP, p < 0.001; 79.1 vs. 83.1 mmHg for diastolic BP, p < 0.01) and higher patient satisfaction (58% vs. 42%, p < 0.001) compared with the control group after 6 mo of follow-up (34) . In a cluster randomized trial, 16 hypertension clinics with pharmacist availability were divided into telemonitoring or usual care clinics. Patients with uncontrolled hypertension were randomized either to usual care with their physician and optional pharmacist education (n = 222) or to telemonitoring with a home BP monitor, pharmacist education, and telehealth visits with pharmacist-led medication titration (n = 228). At 6, 12, and 18 mo, BP met the definition of control in more patients receiving the intervention than usual care (71.8% vs. 45.2%, p < 0.001; 71.2% vs. 52.8%, p = 0.005; 71.8% vs. 57.1%, p = 0.003, respectively). They measured total costs of the intervention and found that the telemonitoring services and pharmacist time would lead to costs of approximately $1350 per patient in a real-world scenario (35) . Although these studies demonstrate the potential benefit of telemedicine in hypertension, it should be noted that there were multiple factors in the intervention groups, with both increased pharmacist titration of BP medications and telemonitoring. It is imperative that studies follow Margolis' (35) example in measuring direct costs per patient for successful implementation to determine whether these programs are feasible and cost-effective.
Other chronic diseases that are highly prevalent in the transplant population have also been a focus for nontransplant mHealth studies. Quinn demonstrated significant improvements in glycosylated hemoglobin (HgA1c) compared with usual care using a phone-based system to track blood glucose (BG) and medication regimens and reporting them, along with treatment recommendations, to physicians regularly (36) . In addition, in a nurse-directed mHealth intervention in recently admitted patients with congestive heart failure patients, Weintraub et al were able to significantly decrease 90-day hospitalizations compared with control patients (hazard ratio 0.5, 95% CI 0.25-0.99; p = 0.05) (37) .
For all the successes in mHealth systems, there are also failures. Some of these may have relied too heavily on patient self-motivation and education, with no health care provider-dependent intervention, such as in the study by Holmen et al of patients with type 2 diabetes in Norway (38) . In this study, 151 patients were randomized to usual care, a mobile phone-based self-management app with wireless BG tracking, or BG tracking plus nurse counseling on diabetes for the first 4 mo of the intervention. All groups received usual care consisting of medical therapy from a physician. After 1 year, there was no difference in HgA1c among the groups.
Despite an attrition rate of only 21%, <40% of patients who remained in the study used the app on a regular basis (38) . Other studies seem to have similar interventions with successful trials but fail to demonstrate a meaningful impact, such as the telemedicine intervention of Koehler et al in patients with chronic heart failure (39) . In this study, 710 patients were randomized to usual care or remote telemonitoring, with a three-lead electrocardiogram, BP monitor, and scale that wirelessly transferred data to a personal digital assistant and then to the caregiver. In the intervention group, a substantial 81% of patients were ≥70% adherent to the daily transfer of data, yet there were no differences in allcause mortality or the composite secondary outcome (39) . Readers are encouraged to see more comprehensive reviews of telemedicine and mHealth in the nontransplant population (40) .
Other outcomes and methodologies may be worth pursuing. The mHealth apps also may be beneficial in combating adverse drug events (ADEs) and their effect on nonadherence. Targeted symptom-based questionnaires have the potential to identify patients with ADEs before they worsen and culminate in an emergency room or hospital admission. Medication history monitoring programs can alert clinicians to new medications from outside prescribers, allowing for intervention for high-risk medications before an ADE. Last, reports on proportion of days covered or mHealth-enabled medication trays or bottles can help identify nonadherence, giving clinicians the opportunity to intervene before the patient has an adverse outcome.
With the prevalence of chronic diseases, ADEs, and nonadherence in SOT recipients, as well as the interrelationships of those factors with allograft outcomes, this population is an ideal one in which to study the potential effectiveness of mHealth. Transplant is one of the few specialties that maintains a long-term relationship with patients, regardless of transplant vintage and geographic distance.
Challenges of Implementation and the Path Forward
The looming question about the cost-effectiveness of mHealth is paramount to its future success and widespread use. The health care community has limited motivation to implement a substantial change without sufficient evidence that it will improve or maintain patient care at a lower cost. To appropriately quantify this, general principles of cost-effectiveness and costminimization studies should be followed and are outside the scope of this review. It is especially important to quantify the cost of training and staff time, in addition to the cost of the production and maintenance, for the mHealth intervention.
Adoption of mHealth by health care providers may be inhibited by the complexity of layered technologies, particularly when considering integration with electronic health records (EHRs) and their associated patient portals. The telehealth industry is increasingly seeking to address these barriers, although this could be expedited through the use of interoperability standards. The importance of EHR interoperability is underscored by the rules governing the Centers for Medicare and Medicaid Services (CMS) EHR Incentive Program, although this is unlikely to be extended to telehealth technologies in the short term. In particular, mHealth devices would benefit from interoperability standards to ease integration with other health software apps, which are increasingly required to organize the large amounts of data being collected. It should be noted that third-party industry participation may serve to mitigate interoperability gaps, although to what extent is currently unknown.
From a clinical point of view, the central theory behind the effectiveness of mHealth rests on a partnership between patients and clinicians. Any mHealth system requires engagement from both parties. Experience with EHRs has illustrated a major concern for clinicians: workflow. If mHealth slows providers down or creates duplicative work, it will not be accepted. There are also concerns about the massive amounts of data being collected, leading to the risk of missing important data points. This would be concerning from both patient care and medicolegal standpoints (41) . To alleviate this concern, a successful mHealth app requires electronic rules built in to alert clinicians to dangerous singular readings or concerning trends in laboratory markers or clinical data. This may occur with or without a health care provider that is specifically tasked with monitoring mHealth and working in collaboration with the patient and the provider. It is evident that many of the successful mHealth systems to date have incorporated pharmacists or nurses as intermediaries or providers (34, 35, 37) .
From a patient perspective, the success of mHealth depends on its ability to support durable changes in patient behavior that improve self-care and shared decision making. Ease of use and perceived utility are critical requirements of the mHealth app; however, motivation for self-management is also important. Bhavnani and colleagues theorized four categories of patients regarding mHealth adoption: high efficiency users, initial adopters, nonadopters, and gradual believers (40) . It is critical for the success of mHealth apps to convert nonadopters and initial adopters into gradual believers, which can be achieved with positive reinforcement and perceived changes or ownership of their health status, coupled with a well-designed, patient-centric mHealth app. Allocating appropriate resources for the training of patients has also proven to be important, as satisfaction with technology training has been shown to significantly increase use of mHealth (23) .
To gain acceptance from the health system and society at large, the app must be cost-effective, save time, and reduce medication errors (42) . To maintain a beneficial effect, it must also be able to produce durable behavioral changes that improve self-care. For this to occur, there must be measurable evident long-term benefits that are sufficiently worth the time that patients and providers allocate to the mHealth app (40) .
Regulations and Reimbursement
The U.S. Food and Drug Administration (FDA) does not regulate apps unless they would pose a risk to patient safety if they did not work as intended or if they are classified as medical devices. The FDA states in a guidance document, "In general, if a mobile app is intended for use in performing a medical device function (i.e. for diagnosis of disease or other conditions, or the cure, mitigation, treatment, or prevention of a disease) it is a medical device, regardless of the platform on which it is run" (43) . Although a lack of FDA oversight for an app significantly reduces the time and effort required from production to implementation, it also places the accuracy, reliability, and data security in the hands of the provider or institution using the technology.
Another limitation on the acceptance of mHealth is the current reimbursement climate from the CMS. Medicare reimburses clinicians for only limited types of Part B services. In addition, these services must meet strict requirements, which currently relate more to nonmobile telemedicine than mHealth. There are significant restrictions regarding the areas in which beneficiaries live, the places where beneficiaries can be present to accept telemedicine services, the types of practitioners allowed, and the method of communication (Figure 1 ). This current reimbursement profile for Medicare beneficiaries severely limits the forward movement of technology and prevents the utilization of some of mHealth's predominant strengths. It is clear that widespread implementation of mHealth into daily clinical practice will require significant modification of reimbursement policies.
Finally, the mobility benefits of mHealth come hand in hand with enhanced data security risk (44, 45) . Although all health-related transmissions create risk, communityand home-based connectivity warrant particular attention to security, as these "last mile" connections are commonly the weakest points. Governance for data security is included in the Health Insurance Portability and Accountability Act and the Health Information Technology for Economic and Clinical Health Act, although there is variability in how well the various technologies currently in use comply (46) . The ability for practitioners to be prudent in minimizing security risk may be difficult without significant resources, which underscores the increasing need to identify and disseminate current best practices (46, 47) .
Conclusion
With all of the potential that mHealth has for the SOT population, it awaits the well-performed studies necessary to gain widespread acceptance from clinicians, hospitals, and insurers. Several areas need research, including methods of patient engagement, optimal mHealth systems to maximize efficiency and minimize cost without overburdening clinicians or patients, and the cost-effectiveness of mHealth interventions. Only when we have furthered this research to the point at which the evidence of mHealth's effectiveness is no longer in doubt will the parties with influence (health care systems, insurers, federal government) give mHealth the boost it needs for mainstream use. SOT remains an ideal population in which to perform these studies. The difference now is that the trajectory of access and familiarity with mobile devices is finally at a high enough level to allow for replicable studies in the entire population and within the SOT community.
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